0JDI.LSE Ionis Pharmaceuticals, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-94.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0JDI.LSE undervalued?

Graham number

The Graham number of Ionis Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ionis Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Ionis Pharmaceuticals, Inc. yet.

Ionis Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe…

Full company profile